Patenting trends by Mexican pharmaceutical companies.

the activity of patent claims by Mexican pharmaceutical companies is unknown. analyse the trend in patents of Mexican pharmaceutical companies. a search for patents was carried out in the patent database of the Mexican Institute of Industrial Property, using the list of Mexican pharmaceutical companies belonging to the Mexican Association of Pharmaceutical Research Industries, and the codes A61K, A61P and C07 of the International Patent Classification.

Drug repurposing of mito-atovaquone for cancer treatment.

Repurposing of approved drugs in a new strategy to combat cancer that leads to savings in time and investment. Atovaquone is a US FDA-approved drug for treatment of pneumonia and malaria. Patent US2023017373 describe the use of mito-atovaquone for the treatment of several types of cancer.

Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody.

PD-L1 and ICOS are immune control points in cancer and their presence in cancer tends to have a poor prognosis. WO2019122882 patent describes a bispecific antibody that targets PDL-1/ICOS with the potential application of cancer treatment. WO2019122882 patent describes a bispecific antibody with antitumor efficacy in CT26 model through of the depletion of T cells and improved ratio of CD8 T cells: T in tumor microenvironment.